RiXtrema in Journal of Fin Planning: DOL Rule Compliance & a Secret Revealed…
Journal of Financial Planning ran a very interesting cover story on advisor technology. RiXtrema’s Don Harding and Daniel Satchkov both answered questions for the magazine. Daniel talked about crucial components of the DOL Fiduciary Rule Solution and Don has revealed the best tech investment for an enterprise under $100. Here is Daniel’s reply to the question...Read More
Michael Kitces covers RiXtrema’s IRAFiduciaryOptimizer and FeeComp database
When we started building tools for advisors after working collectively for decades on software to institutions, I read Michael Kitces almost every day as a way to immerse myself into the issues advisors face. Michael has a way of writing that is intellectual, but clear and concise. That is why I am pleased he mentions...Read More
Now You Can Compare Your Fees To Other Advisors
Hi all, We have released a novel and important database of advisory fees called FeeComp. It is based on SEC form ADV data. We have solved the main problem with that form, namely that fees are reported in Part 2, which essentially is a free form essay i.e. unstructured and very hard to read automatically. Some...Read More
Some Exciting News To Share: 401kFiduciaryOptimizer Is Selected For Fiduciary Certification by CEFEX
401kFiduciaryOptimizer has only been around for 3 months and is already making major waves in the industry. Dozens of advisory firms are using it to take their fiduciary practice to the next level and to grow their business significantly. Now, 401kFO tool has been selected by Centre For Fiduciary Excellence, LLC, an independent certification organization...Read More
This Will Have Tremendous Implications For Your Practice
Something incredibly important just happened in the 401(k) plan sponsor space. An excessive fee lawsuit has been filed against a $9.2M plan with 114 participants. As we’ve been saying for months, smaller plan sponsors better stop being complacent. Conventional wisdom had it that smaller plans can fly under the radar and avoid such lawsuits. False....Read More
Robos Think It’s A Great Time To Buy Risk Assets
Most people who know a bit about financial markets history know that we are in unprecedented territory with central bank stimulus, gratuitous buybacks, widespread accounting shenanigans. But robo-advisors apparently think it is a great time to buy risk assets. Check out this Morning Markets Briefing from Convergex (subscription is free) in an article called Millenials...Read More
Negative Rates – Welcome To Beyond The Looking Glass
Wow, just listen to all the chatter about negative interest rates! The question in my mind is not if this economic twilight zone is coming to the United States, but rather when. Japan, after all, had a decent head start to the rest of the world in terms of QE policies, so it may take...Read More
New Risks in 2016 and New Scenarios For Your Client Meetings
Dear colleague, happy new year! 2016 is shaping up to be an extremely volatile year to say the least. The key risks for 2016 stem from two factors: Sharp drop in energy prices that persists Fed starting to raise rates Energy has had historic declines in 2015. The main issue is not the oil price...Read More
Frontrunning Goes Full Star Wars: Uses Trading Lighsaber
By now most of market participants are aware of the ubiquitous front running going on in the markets. Michael Lewis detailed only some of its aspects in its excellent Flash Boys. Here is some amazing investigative work that uncovered that frontrunning is now almost literally Star Wars, with lasers being used to outrun regular investors....Read More
Article by RiXtrema Authors Wins 2015 Peter L. Bernstein Award – Journal of Derivatives, published by Institutional Investor Journals
An article in the Journal of Derivatives, published by Institutional Investor Journals, has been named the winner of the 2015 Peter L. Bernstein Award. Risk Estimation and Hedging: A Reverse Stress Testing Approach – written by Yaacov Kopeliovich, Arcady Novosyolov, Daniel Satchkov and Barry Schachter (all authors associated with RiXtrema) — investigates a recent innovation...Read More